Dissemination of Clonally Related Escherichia coli Strains Expressing Extended-Spectrum β-Lactamase CTX-M-15

Teresa M. Coque,*†‡ Ângela Novais,*†‡ Alessandra Carattoli,§ Laurent Poirel,¶ Johann Pitout,#** Luísa Peixe,†† Fernando Baquero,*†‡ Rafael Cantón,*†‡ and Patrice Nordmann¶

We analyzed 43 CTX-M-15-producing Escherichia coli isolates and 6 plasmids encoding the $\textit{bla}_{\text{CTX-M-15}}$ gene from Canada, India, Kuwait, France, Switzerland, Portugal, and Spain. Most isolates belonged to phylogroups B2 (50%) and D (25%). An EC-B2 strain of clonal complex sequence type (ST) 131 was detected in all countries; other B2 isolates corresponded to ST28, ST405, ST354, and ST695 from specific areas. EC-D strains were clonally unrelated but isolates from 3 countries belonged to ST405. All CTX-M-15 plasmids corresponded to IncFII group with overrepresentation of 3 Hpal-digested plasmid DNA profiles (A, B and C; 85–120kb, similarity ≥70%). Plasmid A was detected in EC-B2 strains (ST131, ST354, or ST405), plasmid C was detected in B2 and D strains, and plasmid B was confined to worldwide-disseminated ST131. Most plasmids contained *bla*_{OXA-1}, *aac*(6')-*lb-cr*, and *bla*_{TEM-1}. Worldwide dissemination of CTX-M-15 seems to be determined by clonal complexes ST131 and ST405 and multidrug-resistant IncFII plasmids.

Plasmid-mediated CTX-M type expanded-spectrum β lactamases (ESBLs), which have been extensively reported for the past 10 years, are detected mostly in community-acquired pathogens and are associated mainly with *Escherichia coli*. These β -lactamases compromise the ef-

*Hospital Universitario Ramón y Cajal, Madrid, Spain; †Unidad de Resistencia a Antibióticos y Virulencia Bacteriana Asociada al Consejo Superior de Investigaciones Científicas, Madrid, Spain; ‡El Consorcio de Investigación Biomédica en Red de Epidemiología y Salud Pública, Madrid, Spain; §Istituto Superiore di Sanità, Rome, Italy; ¶Hospital Bicetre, Paris, France; #Calgary Laboratory Services, Calgary, Alberta, Canada; **University of Calgary, Calgary, Alberta, Canada; and ††Universidade do Porto, Porto, Portugal ficacy of all β -lactams, except carbapenems and cephamycins, and are associated with many non- β -lactam resistance markers because of their locations on plasmids. Therefore, they may constitute a real threat for treating communityacquired *E. coli*-mediated urinary tract infections (1,2).

Different variants of CTX-M ESBLs are grouped in 5 clusters, although their distribution varies greatly depending on the geographic area (www.lahey.org/studies/webt. htm). CTX-M-15, which was first detected in isolates from India in 2001 (3), is now recognized as the most widely distributed CTX-M enzyme. It is derived from CTX-M-3 by 1 amino acid substitution at position 240 (Asp-240 \rightarrow Gly), which apparently confers an increased catalytic activity to ceftazidime (4). Clonal outbreaks of CTX-M-15-producing Enterobacteriaceae have been reported in France, Italy, Spain, Portugal, Austria, Norway, the United Kingdom, Tunisia, South Korea, and Canada, and E. coli is the most frequently involved species. Within E. coli, CTX-M-15-producing strains of the B2 phylogenetic group are commonly found and frequently harbor multidrug resistance and virulence determinants (5-18).

Plasmids encoding $bla_{CTX-M-15}$ have been isolated from clinical isolates in France, Spain, Portugal, the United Kingdom, Canada, India, Pakistan, South Korea, Taiwan, the United Arabic Emirates, and Honduras (5–8, 10,11,15,19,20). Plasmid characterization, which has only been accomplished for those plasmids from Canada, France, Spain, and the United Kingdom, classified most of them as members of incompatibility group FII (5,7,8,17,19).

Lack of detailed studies on isolates expressing particular CTX-Ms from different geographic areas has precluded identification of factors involved in recent and worldwide

RESEARCH

spread of specific CTX-M variants. In this article, through analysis of the population biology of CTX-M-15–producing isolates from 7 countries and characterization of their genetic elements, we provide a comprehensive picture of elements involved in international spread of a particularly widespread mechanism of antimicrobial drug resistance.

Materials and Methods

Bacterial Strains, Production of ESBL, and Susceptibility Testing

We studied 43 CTX-M-15-producing E. coli clinical isolates from France (n = 17), Kuwait (n = 9), Switzerland (n = 7), Canada (n = 4), Portugal (n = 3) and Spain (n = 3)3), and 6 CTX-M-15 plasmids from India (3), all obtained from 2000 through 2006. These strains and plasmids were considered representative of these areas because they either caused outbreaks or were the first isolates recovered in those countries (3,11,16,19,21–23). Samples were isolated from urine (n = 33/43, 77%), wounds (n = 4/43, 77%)9.%), respiratory tract infections (n = 3/43, 7%) and other sites (1 from feces, 1 from an intravenous catheter, and 1 from blood) in hospitalized patients. ESBL production was confirmed by a standard double-disk synergy test, and *bla* genes were characterized by PCR and additional sequencing as described (19). Susceptibility patterns to 13 non–β-lactam antimicrobial drugs were determined by the standard disk diffusion method following published standards (24). Strains with intermediate susceptibility were considered resistant.

Clonal Relationships

Clonal relationships were established by pulsed-field gel electrophoresis (PFGE) of *Xba*I-digested genomic DNA (New England Biolabs, Ipswich, MA, USA) as described (25). Assignment of *E. coli* phylogenetic groups was conducted by using a multiplex PCR assay described by Clermont et al. (26). All *E. coli* isolates belonging to phylogroups B2 and D were characterized by multilocus sequence typing (MLST) using the standard 7 housekeeping loci (www.mlst.net). All *fumC* sequences from *E. coli* isolates belonging to phylogroup D were analyzed for a C288T single nucleotide polymorphism. This polymorphism is specific for a globally disseminated *E. coli* strain arbitrarily designated as *E. coli* clonal group A (CgA) that is associated with community-acquired urinary tract infections (27,28).

Transferability and Location of bla_{CTX-M-15}

Transferability was tested by broth and filter mating assays using *E. coli* K12 strain BM21R (resistant to nalidixic acid and rifampin, positive for lactose fermentation, and free of plasmids) as recipient at a 1:2 donor: recipient

ratio. Transconjugants were selected on Luria-Bertani agar plates containing cefotaxime (1 mg/L) and rifampin (100 mg/L) and incubated at 37°C for 24–48 h. Transformation was performed for a subset of isolates by using conditions reported (3). Chromosomal or plasmid location of $bla_{CTX-M-15}$ genes was assessed by hybridization of I-*Ceu*I–digested genomic DNA with $bla_{CTX-M-15}$ and 16S rDNA probes and electrophoresis (5–25 s for 23 h and 60–120 s for 10 h at 14°C and 6 V/cm²) (25). Transfer and hybridization were performed by using standard procedures. Labeling and detection were conducted by using enhanced chemiluminescence (Amersham Life Sciences, Uppsala, Sweden) following manufacturer's instructions.

Plasmid Characterization

Plasmid DNA was obtained by using different midiprep plasmid purification kits (QIAGEN, Hilden, Germany, and Marlingen Biosciences, Ijamsville, MD, USA). Plasmids were classified according to their incompatibility group by a PCR-based replicon-typing scheme (29). Determination of plasmid size and confirmation of replicon content was established for transconjugants (or wild-type strains in the absence of transfer) by hybridization of S1 nuclease-digested genomic DNA with probes specific for *bla*_{CTX-M-15} and for different F replicons (FII, FIA, FIB), which were obtained by PCR as described (19). Relationships among plasmids were determined by comparison of EcoRI and HpaI digested DNA patterns and comparison of repFII sequences. Genescan software (Applied Biosystems, Foster City, CA, USA) was used for collection of gel images. Data of a subset of representative patterns were exported into Fingerprinting II Informatix version 3.0 software (Bio-Rad Laboratories, Hercules, CA, USA) for further interpretation. Cluster analysis was conducted by using the unweighted pair group method with arithmetic averages (optimization 0.5%, tolerance 1.00%).

Presence of genes previously associated with plasmids encoding CTX-M-15 as bla_{OXA-1} , bla_{TEM-1} , and aac(6')-*lb-cr* was screened by PCR by using primers bla_{OXA-1} (oxa1 FW: 5'-TTT TCT GTT GTT TGG GTT TT-3' and oxa1 RV: 5'-TTT CTT GGC TTT TAT GCT TG-3'), bla_{TEM-1} (TEM-F: 5'-ATG AGT ATT CAA CAT TTC CG-3' and TEM-R: 5'-CTG ACA GTT ACC AAT GCT TA-3'), and aac(6')*lb-cr* (aac-cr-F: 5'-TTG CGA TGC TCT ATG AGT GG-3' and aac-cr-R: 5'-GCG TGT TCG CTC GAA TGC C-3') (*11,19,30*). Additional sequencing was necessary to identify the corresponding genes.

Results

Epidemiologic Background

Most CTX-M-15–producing *E. coli* isolates belonged to phylogroups B2 (50%) and D (25%), which are known

to be associated with the hospital setting and extraintestinal pathogenic E. coli. Phylogroups A (18%) and B1 (7%), which are associated with animal or human commensal strains, were less frequently represented. All isolates of phylogroups B2, A, and D corresponded to subgroups B2, A₁, and D₁, respectively, which are the most common ones within each phylogenetic group (31). The 43 clinical isolates were classified into 32 PFGE types (B2, 13; D, 10; A₁, 6; and B1, 3). Among B2₃ strains, 10 PFGE types (18 isolates from France, Canada, Spain, Portugal, Kuwait, and Switzerland) were possibly related according to criteria of Tenover et al. (32) (difference <6 bands, >80% similarity) and were assigned to the sequence type (ST) ST131. The 4 unrelated B2 strains were classified within ST695 (1 from France), ST28 (1 from Switzerland), ST354 (1 from Portugal and Spain) and ST405 (1 from Portugal). All isolates of phylogroup D₁ were clonally unrelated by PFGE (difference >6 bands), although MLST studies indicated that 4 PFGE types (5 isolates) from Kuwait, Switzerland, and Spain corresponded to ST405. The *fumC* sequences of the remaining 6 E. coli D strains were highly diverse (alleles 4, 13, 26, 88, and 132). None of the strains had the C288T single nucleotide polymorphism specific for E. coli strain CgA (28). All 3 B1 isolates were found in France. Among B2 E. coli isolates, all but 4 were isolated from urine and all but 2 belonged to ST131. These strains correspond to 2 isolates recovered from wounds and identified as ST28 and ST354 and 2 ST131 isolates from respiratory and fecal samples, respectively.

CTX-M-15 clinical strains were considered resistant to different antimicrobial drugs: amoxicillin-clavulanate (98%), tobramycin (89%), kanamycin (87%), tetracycline (84%), gentamicin (82%), nalidixic acid (74%), streptomycin (68%), sulfonamides (61%), ciprofloxacin (61%), trimethoprim (58%), chloramphenicol (21%), nitrofurantoin (12%), and amikacin (11%). All CTX-M-15 transconjugants expressed resistance to aminoglycosides, tetracycline, or trimethoprim. All but 2 strains contained *bla*_{OXA-1} and *aac*(6')-*Ib-cr*; 1 contained only *aac*(6')-*Ib-cr*, and 1 contained *bla*_{OXA-1} and *aacA4*, which confers reduced susceptibility to amikacin and kanamycin.

Location and Transferability of *bla*_{CTX-M-15}

The $bla_{\text{CTX-M-15}}$ gene was located on plasmids in all but 6 strains and was positively transferred by conjugation or transformation in 37% of the strains tested. In 8 clinical isolates corresponding to 7 PFGE types, the probe for $bla_{\text{CTX-M-15}}$ hybridized in chromosomal bands (2 belonging to B2₃ ST131, 2 to D₁, 1 to D₁ ST405, and 1 to A₁). In 2 other strains, the $bla_{\text{CTX-M-15}}$ probe hybridized both with plasmid and chromosomal bands (1 strain from D ST405 and 1 from phylogroup B1).

Plasmids Encoding CTX-M-15

Plasmids positive for the *bla*_{CTX-M-15} gene showed variable sizes (85-160 kb), belonged to the narrow host range incompatibility group IncF, and had replicon FII alone or in association with the FIA or FIB replicons (online Appendix Table, available from www.cdc.gov/EID/content/14/2/ 195-appT.htm). Many restriction fragment length polymorphism (RFLP) patterns were observed, with overrepresentation of 3 profiles corresponding to 3 plasmids arbitrarily designated as plasmid A (85 kb), plasmid B (120 kb), and plasmid C (85 kb). Plasmid A, which was isolated from B2 E. coli strains from 4 countries (India, France, Portugal, and Spain), was associated with different STs (ST131, ST354, or ST405). Plasmid C was also detected in clonally unrelated E. coli of phylogroups B2 and D from Switzerland, Canada and France. Plasmid B, which was only associated with E. coli ST131, was widely disseminated in all countries studied. Sequence analysis of the replicons showed 4 repFII types: repFII(1), which was identical to that of plasmids R100, NR1, or pC15-1a, and was the most represented and identified in 23 plasmids; repFII(2), which had 99%-100% homology with plasmid pRSB107 (Gen-Bank accession no. AJ851089), was identified in 6 plasmids; and repFII(3) and repFII(4), which were detected in 2 and 7 plasmids, respectively, and showed >93% homology with repFII(1). All repFIA and repFIB sequences were 99% and 100% homologous, respectively, with that of pRSB107 (GenBank accession no. AJ851089).

Computer analysis of representative RFLP patterns and repFII sequences grouped CTX-M-15 plasmids within 3 major clusters with similarity >70%. Cluster I comprises most plasmids, including plasmids A and B, most containing repFII(1) and showing variable replicon content. Cluster II comprised only plasmid C derivatives showing slightly different repFII sequences, and cluster III included 2 plasmids carrying repFII(2), FIA, and FIB replicons (Figure).

In the 8 strains with chromosomal location of $bla_{CTX-M-15}$, repFII plasmids were identified but these plasmids were negative for the $bla_{CTX-M-15}$ gene. Several strains that were also positive for additional plasmids and negative for the $bla_{CTX-M-15}$ gene were assigned to different incompatibility groups or were untypeable by the PCR-based replicon typing scheme used.

Discussion

Our study indicates that current worldwide spread of the $bla_{CTX-M-15}$ gene is driven mainly by 2 epidemic *E. coli* strains belonging to phylogroups B2 (ST131) and D (ST405) and by its location on IncF plasmids harboring multiple antimicrobial drug–resistance determinants, including the recently described aac(6')-*Ib-cr* gene. The presence of $bla_{CTX-M-15}$ has previously been associated with *E. coli* strains of phylogroups B2 and D, and in some instances, with

RESEARCH



Figure. Computer analysis of a subset of representative *Hpal* restriction profiles of IncF CTX-M-15 plasmids from *Escherichia coli* isolates in the Appendix Table. Cluster analysis was done by using Fingerprinting II in Informatix software version 3.0 (Bio-Rad Laboratories, Hercules, CA, USA) and applying the unweighted pair group method with arithmetic averages (optimization 0.5%, tolerance 1.00%). Ph, phylogenetic; ST, sequence type; RFLP, restriction fragment length polymorphism; Can, Canada; Fra, France; Por, Portugal; Swi, Switzerland; Ind, India; Kuw, Kuwait; Sp, Spain.

specific PFGE types (9–12,16). We detected an emerging and globally disseminated CTX-M-15 phylogroup B2 *E. coli* strain corresponding to the ST131 that was responsible for clonal outbreaks in Canada, France, Spain, and Portugal (11,14,16,23). Other CTX-M-15 B2 strains belong to clonal complexes ST695, ST405, ST354, or ST28, which have previously been detected in different geographic areas among isolates that do not express CTX-M-15 (online Appendix Figure, available from www.cdc.gov/EID/content/14/2/195-appG.htm).

Globally disseminated E. coli strains associated with acute, uncomplicated, community-acquired cystitis and pyelonephritis, designated in community patients as clone CgA (ST69), have only been occasionally associated with CTX-M-15 production in Canada (16,27,28). Although the isolates in our study do not belong to clone CgA, they were isolated mainly from urine samples, and an association of ST131 E. coli isolates with urinary tract infections might be inferred. Although most CTX-M-15 isolates studied were recovered from hospitalized patients, these microorganisms are now widely spread in the community setting, including long-term care facilities in the countries from which isolates included in this study originated (2,5,14,33). Our study has increased knowledge of the number of epidemic E. coli clonal complexes causing urinary tract infections.

All plasmids carrying $bla_{CTX-M-15}$ included in this study corresponded to incompatibility group F, and all had the FII replicon, which was assorted mainly in multireplicon plasmids with additional replicons of the FIA and FIB types. Association of the $bla_{CTX-M-15}$ gene with IncFII replicons has been described in studies conducted in Canada, France, Spain, and the United Kingdom (5,7,8,17,19). Although we observed intercontinental dissemination of 3 major IncFII plasmid scaffolds (A, B, and C) carrying $bla_{CTX-M-15}$, similarity >70% among all variants studied and presence of genes also found in pC15–1a, a CTX-M-15 plasmid (Gen-Bank accession no. AY458016) that has a 28.4-kb multidrug resistance region containing bla_{TEM-1} , bla_{OXA-1} , the aac(6')-*Ib-cr* gene (aminoglycoside 6'-N-acetyltransferase type Ib-cr variant responsible for reduced susceptibility to both aminoglycosides and certain fluoroquinolones), and genetic determinants coding for resistance to tetracycline and aminoglycosides (5,30), suggest a common origin or a common particular plasmid scaffold involved in the dissemination of CTX-M-15.

Because IncF plasmids are a heterogeneous and largely diffused family of plasmids in E. coli, they could acquire the *bla*_{CTX-M-15} gene. IncF plasmids negative for the bla_{CTX-M-15} gene in strains with this gene at a chromosomal location also suggest dynamic horizontal exchanges between the chromosome and resident plasmids. Extensive recombination events among IncF plasmids are frequent and may have contributed to their apparent high diversity (variable rep content, plasmid size, transferability, antimicrobial drug-resistance genes), driving their evolution and enabling them to persist in diverse E. coli populations (34,35). Such recombination events among plasmids of the same incompatibility group within the same cell occur frequently (34,35). This hypothesis is supported by the results of Lavollay et al. (17), who described mosaicism in a CTX-M-15 plasmid isolated in France that contained genes from 2 different IncFII plasmids, pC15-1a and pRSB107 (from IncFII plasmids first isolated from persons in Canada and activated sludge bacteria from a wastewater treatment plant in Germany, respectively) (5,36).

Spread and maintenance of conjugative plasmids across bacterial populations have been intensively studied from a theoretical point of view, but data from natural populations are scarce (34,37,38). Recovery of related plasmids from clonally unrelated B2 strains might reflect efficient transfer of these elements among different B2 E. coli populations. Sharing the same environment, successive immigrant B2 strains might sweep through the population, enabling plasmid hitchhiking at a high frequency in each selective sweep. However, we lack detailed information on the specificity and stability of different plasmid groups in specific hosts. An evolutionary convergent relationship among B2 genetic background and IncFII plasmids cannot be ruled out and should be studied because it might explain successful dissemination of CTX-M-15 plasmids within this E. coli lineage. In addition, our study is one of the few that have identified bla_{ESBL} genes in the chromosome, which might respond either to plasmid integration or transposition driven by ISEcp1 located upstream from the *bla*_{CTX-M-15} gene (25,39,40).

In conclusion, worldwide dissemination of $bla_{CTX-M-15}$ is driven by B2 or D *E. coli* clones associated mainly with urinary tract infections or IncFII plasmids containing a multiple antimicrobial drug–resistance platform that contributes to spread of CTX-M-15. Further studies to test the stability/variability and fitness of particular plasmids among different bacterial hosts will be relevant in developing additional strategies to control dissemination of antimicrobial drug resistance.

Acknowledgments

We thank C. de Champs, A. Wenger, and V. Rotimi for providing some of the strains used in this study.

This work was partially supported by research grants from the Ministerio de Ciencia y Tecnología of Spain (grant SAF 2003-09285) to T.M.C. and the European Commission (grants LSHM-CT-2003-503335 and LSHM-CT-2005-018705). A.N. was supported by fellowships from the Ministerio de Ciencia y Tecnología of Spain (SAF 2003-09285) and the Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública.

Dr Coque is a senior scientist in the Microbiology Department at the Hospital Universitario Ramón y Cajal in Madrid. Her research interests include the molecular epidemiology, ecology, and evolution of antimicrobial drug–resistant *Enterobacteriaceae* and *Enterococcus*.

References

- Cantón R, Coque TM. The CTX-M beta-lactamase pandemic. Curr Opin Microbiol. 2006;9:466–75.
- 2. Livermore DM, Canton R, Gniadkowski M, Nordmann P, Rossolini GM, Arlet G, et al. CTX-M: changing the face of ESBLs in Europe. J Antimicrob Chemother. 2007;59:165–74.
- Karim A, Poirel L, Nagarajan S, Nordmann P. Plasmid-mediated extended-spectrum beta-lactamase (CTX-M-3 like) from India and gene association with insertion sequence ISEcp1. FEMS Microbiol Lett. 2001;201:237–41.
- Poirel L, Gniadkowski M, Nordmann P. Biochemical analysis of the ceftazidime-hydrolysing extended-spectrum beta-lactamase CTX-M-15 and of its structurally related beta-lactamase CTX-M-3. J Antimicrob Chemother. 2002;50:1031–4.
- Boyd DA, Tyler S, Christianson S, McGeer A, Muller MP, Willey BM, et al. Complete nucleotide sequence of a 92-kilobase plasmid harboring the CTX-M-15 extended-spectrum beta-lactamase involved in an outbreak in long-term-care facilities in Toronto, Canada. Antimicrob Agents Chemother. 2004;48:3758–64.
- Eisner A, Fagan EJ, Feierl G, Kessler HH, Marth E, Livermore DM, et al. Emergence of *Enterobacteriaceae* isolates producing CTX-M extended-spectrum beta-lactamase in Austria. Antimicrob Agents Chemother. 2006;50:785–7.
- Hopkins KL, Liebana E, Villa L, Batchelor M, Threlfall EJ, Carattoli A. Replicon typing of plasmids carrying CTX-M or CMY beta-lactamases circulating among *Salmonella* and *Escherichia coli* isolates. Antimicrob Agents Chemother. 2006;50:3203–6.
- Karisik E, Ellington MJ, Pike R, Warren RE, Livermore DM, Woodford N. Molecular characterization of plasmids encoding CTX-M-15 beta-lactamases from *Escherichia coli* strains in the United Kingdom. J Antimicrob Chemother. 2006;58:665–8.

- Lavigne JP, Marchandin H, Delmas J, Moreau J, Bouziges N, Lecaillon E, et al. CTX-M–producing *Escherichia coli* in French hospitals: prevalence, molecular epidemiology, and risk factors. J Clin Microbiol. 2006;45:620–6.
- Leflon-Guibout V, Jurand C, Bonacorsi S, Espinasse F, Guelfi MC, Duportail F, et al. Emergence and spread of three clonally related virulent isolates of CTX-M-15–producing *Escherichia coli* with variable resistance to aminoglycosides and tetracycline in a French geriatric hospital. Antimicrob Agents Chemother. 2004;48: 3736–42.
- Machado E, Coque TM, Cantón R, Baquero F, Sousa JC, Peixe L. Dissemination of *Enterobacteriaceae* harboring *bla*_{CTX-M-15}, *bla*_{0XA-1}, *bla*_{TEM-1} and *aac(6')-Ib-cr* gene in Portugal. Antimicrob Agents Chemother. 2006;50:3220–1.
- Mamlouk K, Boutiba-Ben Boubaker I, Gautier V, Vimont S, Picard B, Ben Redjeb S, et al. Emergence and outbreaks of CTX-M betalactamase–producing *Escherichia coli* and *Klebsiella pneumoniae* strains in a Tunisian hospital. J Clin Microbiol. 2006;44:4049–56.
- Mugnaioli C, Luzzaro F, de Luca F, Brigante G, Perilli M, Amicosante G, et al. CTX-M-Type extended-spectrum beta-lactamases in Italy: molecular epidemiology of an emerging countrywide problem. Antimicrob Agents Chemother. 2006;50:2700–6.
- Oteo J, Navarro C, Cercenado E, Delgado-Iribarren A, Wilhelmi I, Orden B, et al. Spread of *Escherichia coli* strains with high-level cefotaxime and ceftazidime resistance between the community, long-term care facilities, and hospital institutions. J Clin Microbiol. 2006;44:2359–66.
- Pai H, Kim MR, Seo MR, Choi TY, Oh SH. A nosocomial outbreak of *Escherichia coli* producing CTX-M-15 and OXA-30 beta-lactamase. Infect Control Hosp Epidemiol. 2006;27:312–4.
- Pitout JD, Laupland KB, Church DL, Menard ML, Johnson JR. Virulence factors of *Escherichia coli* isolates that produce CTX-M-type extended-spectrum beta-lactamases. Antimicrob Agents Chemother. 2005;49:4667–70.
- Lavollay M, Mamlouk K, Frank T, Akpabie A, Burghoffer B, Ben Redjeb RS, et al. Clonal dissemination of a CTX-M-15 beta-lactamase–producing *Escherichia coli* strain in the Paris area, Tunis, and Bangui. Antimicrob Agents Chemother. 2006;50:2433–8.
- Naseer U, Natas OB, Haldorsen BC, Bue B, Grundt H, Walsh TR, et al. Nosocomial outbreak of CTX-M-15–producing *E. coli* in Norway. APMIS. 2007;115:120–6.
- Novais A, Cantón R, Moreira R, Peixe L, Baquero F, Coque TM. Emergence and dissemination of *Enterobacteriaceae* isolates producing CTX-M-1–like enzymes in Spain are associated with IncFII (CTX-M-15) and broad-host-range (CTX-M-1, -3, and -32) plasmids. Antimicrob Agents Chemother. 2007;51:796–9.
- Sonnevend A, Al Dhaheri K, Mag T, Herpay M, Kolodziejek J, Nowotny N, et al. CTX-M-15–producing multidrug-resistant enteroaggregative *Escherichia coli* in the United Arab Emirates. Clin Microbiol Infect. 2006;12:582–5.
- Lartigue MF, Fortineau N, Nordmann P. Spread of novel expanded-spectrum beta-lactamases in *Enterobacteriaceae* in a university hospital in the Paris area, France. Clin Microbiol Infect. 2005;11: 588–91.
- Lartigue MF, Zinsius C, Wenger A, Bille J, Poirel L, Nordmann P. Extended-spectrum beta-lactamases of the CTX-M type now in Switzerland. Antimicrob Agents Chemother. 2007;51:2855–60.
- Brasme L, Nordmann P, Fidel F, Lartigue MF, Bajolet O, Poirel L, et al. Incidence of class A extended-spectrum (beta)-lactamases in Champagne-Ardenne (France): a 1-year prospective study. J Antimicrob Chemother. 2007;60:956–64.
- 24. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial disk susceptibility tests. Approved standard. 9th ed. Document M2–A9. Wayne (PA): The Institute; 2006.

RESEARCH

- 25. Novais A, Cantón R, Valverde A, Machado E, Galán JC, Peixe L, et al. Dissemination and persistence of *bla*_{CTX-M-9} are linked to class 1 integrons containing CR1 associated with defective transposon derivatives from Tn*402* located in early antibiotic resistance plasmids of IncHI2, IncP1-alpha, and IncFI groups. Antimicrob Agents Chemother. 2006;50:2741–50.
- Clermont O, Bonacorsi S, Bingen E. Rapid and simple determination of the *Escherichia coli* phylogenetic group. Appl Environ Microbiol. 2000;66:4555–8.
- Johnson JR, Murray AC, Kuskowski MA, Schubert S, Prere MF, Picard B, et al.; Trans-Global Initiative for Antimicrobial Resistance Initiative (TIARA) Investigators. Distribution and characteristics of *Escherichia coli* clonal group A. Emerg Infect Dis. 2005;11:141–5.
- Tartof SY, Solberg OD, Manges AR, Riley LW. Analysis of a uropathogenic *Escherichia coli* clonal group by multilocus sequence typing. J Clin Microbiol. 2005;43:5860–4.
- Carattoli A, Bertini A, Villa L, Falbo V, Hopkins KL, Threlfall EJ. Identification of plasmids by PCR-based replicon typing. J Microbiol Methods. 2005;63:219–28.
- Robicsek A, Strahilevitz J, Jacoby GA, Macielag M, Abbanat D, Park CH, et al. Fluoroquinolone-modifying enzyme: a new adaptation of a common aminoglycoside acetyltransferase. Nat Med. 2006;12:83–8.
- Branger C, Zamfir O, Geoffroy S, Laurans G, Arlet G, Thien HV, et al. Genetic background of *Escherichia coli* and extended-spectrum beta-lactamase type. Emerg Infect Dis. 2005;11:54–61.
- Tenover FC, Arbeit RD, Goering RV, Mickelsen PA, Murray BE, Persing DE, et al. Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing. J Clin Microbiol. 1995;33:2233–9.
- Kassis-Chikhani N, Vimont S, Asselat K, Tivalle C, Minassian B, Sengelin C, et al. CTX-M beta-lactamase–producing *Escherichia coli* in long-term care facilities in France. Emerg Infect Dis. 2004;10:1697–8.

- Levin BR. Conditions for evolution of multiple antibiotic resistant plasmids: a theoretical and experimental excursion. In: Baumberg S, Young PW, Wellington EM, Saunders JR, editors. Population genetics of bacteria. Cambridge: Cambridge University Press; 1995. p. 175–92.
- Osborn AM, da Silva Tatley FM, Steyn LM, Pickup RW, Saunders JR. Mosaic plasmids and mosaic replicons: evolutionary lessons from the analysis of genetic diversity in IncFII-related replicons. Microbiology. 2000;146:2267–75.
- 36. Szczepanowski R, Braun S, Riedel V, Schneiker S, Krahn I, Puhler A, et al. The 120 592 bp IncF plasmid pRSB107 isolated from a sewage-treatment plant encodes nine different antibiotic-resistance determinants, two iron-acquisition systems and other putative virulence-associated functions. Microbiology. 2005;151:1095–111.
- Bergstrom CT, Lipsitch M, Levin BR. Natural selection, infectious transfer and the existence conditions for bacterial plasmids. Genetics. 2000;155:1505–19.
- Dionisio F, Conceição IC, Marques AC, Fernandes L, Gordo I. The evolution of a conjugative plasmid and its ability to increase bacterial fitness. Biol Lett. 2005;1:250–2.
- Poirel L, Lartigue MF, Decousser JW, Nordmann P. ISEcp1B-mediated transposition of *bla*_{CTX-M} in *Escherichia coli*. Antimicrob Agents Chemother. 2005;49:447–50.
- Yagi T, Kurokawa H, Senda K, Ichiyama S, Ito H, Ohsuka S, et al. Nosocomial spread of cephem-resistant *Escherichia coli* strains carrying multiple Toho-1–like beta-lactamase genes. Antimicrob Agents Chemother. 1997;41:2606–11.

Address for correspondence: Teresa M. Coque, Servicio de Microbiología, Hospital Universitario Ramón y Cajal, Carretera de Colmenar, Km 9, Madrid 28034, Spain; email: mcoque.hrc@salud.madrid.org

EMERGING Full text free online at www.cdc.gov/eid	
The print journal is available at no charge to public health professionals YES, I would like to receive Emerging Infectious Diseases.	
Please print your name and business address in the box and return by fax to 404-639-1954 or mail to EID Editor CDC/NCID/MS D61 1600 Clifton Road, NE Atlanta, GA 30333	EID
Moving? Please give us your new address (in the box) and print the number of your old mailing label here	www.cdc.gov/eid

										Plasmid features	
					Isolate		Antimicrobial drug				RFLP
EC PhG	Location	Origin	Date	PFGE type	no.	MLST	resistance pattern†	<i>bla</i> _{CTX-M-15} ‡	Size, kb§	rep content¶	type#
B2 ₃	Portugal, Spain	Urine	2002–2003	C15–1	2	ST354	Ac, Gm, Km, Na, (Ni), Sm, Su, Tb, Tp	P (85)	85	FII (85)	A
B2 ₃	Portugal	Wound	2003	C15–2	1	ST405	Ac, Gm, Km, Na, Ni, Sm, Su. Tb. Tp	P (85)	85	FII (85)	А
B23	Paris, France, Portugal	Catheter (n = 1), urine (n = 1)	2001–2004	C15–3	2	ST131	Ac, Cp, Gm, Km, Na, Sm, Su, Tc, Tb, Tp	P (85)	85	FII (85)	A
_	India		2000	C15–4	1	_	Ac, Gm, Km, Sm, Tb, Tc	P (85)	85	FII (85)	А
_	India	-	2000	C15–5	1	_	Ac, Gm, Km, Sm, Tb, Tc	P (85)	85	FII (85)	А
_	India	-	2000	C15–6	1	_	Ac, Gm, Km, Sm, Tb, Tc	P (85)	85	FII (85)	А
_	India	_	2000	C15–7	1	_	Ac. Gm. Km. Sm. Tb. Tc	P (120)	120	FII + FIA (120)	В
B2₃	Kuwait	Urine	2004	C15–3a	1	ST131	Ac. Cp. Na. Te	P (120)	120	FII + FIA (120)	В
B2 ₃	Switzerland	Urine	2004	C15–3b	1	ST131	Ac, Cp, Gm, Km, Na, Tc,	C	120	FII + FIA (120)	В
B2 ₃	Canada,	Urine (n =	2000–2002	C15–3c	2	ST131	Ac, Cp, Gm, Km, Na, Tc,	P (120)	120	FII + FIA (120)	В
B23	Portugal, Canada, Paris France	Urine (n = 2)	2001–2004	C15–3d	3	ST131	Ac, (Cp), (Gm), (Km), Na, (Sm), (Tc), (Tb)	P (120), n = 1; C, n = 2	120	FII + FIA (120)	В
B23	Paris and Reims,	Urine (n = 3), feces (n	2003–2005	C15–3e	4	ST131	Ac, (Cp), (Gm), (Km), Na, (Sm), (Tc), (Tb)	С	120	FII + FIA (120)	ND
B2 ₃	Reims, France	Urine	2005	C15–3f	1	ST131	Ac, Cp, Na	P (150)	150	FII + FIA + FIB (150)	FE
B2 ₃	Kuwait	Urine	2004	C15–3g	1	ST131	Ac, Cp, Gm, Km, Na, Sm, Tc, Tb, Su, Tp	P (100)	100 + 150	FII + FIB (100)	ND
B2 ₃	Switzerland	Urine	2004	C15–3h	1	ST131	Ac, Cp, Gm, Km, Na, Su, Tc, Tb, Tp	P (160)	160	FII + FIA (160)	Ν
B2₂	Paris France	Urine	2000	C15-8	1	ST695	Ac. Na. Sm. Su. Tc. Tp	P (85)	85	FII + FIB (85)	C1
B2₀	Switzerland	Wound	2004	C15–9	1	ST28	Ac	P (85)	85 + 120	FII (85)	C1
D ₁	Switzerland	Respiratory	2004	C15–10	1	fumC 13	Ac, Gm, Km, Tc, Tb,	P (110)	110	FII + FIB (110)	E
D ₁	Paris, France	Urine	2000	C15–11	1	fumC 26	Ac, Ak, Cp, Cm, Gm, Km, Na, Sm, Su, Tc , Th, Tp ,	P (100)	100	FII (100)	ND
D ₁	Spain	Wound	2002	C15–12	1	ST405	Ac, Cm, Gm, Km, Na, Sm, Su Tc Th Tn	P (100)	100 + 120	FII + FIA (100)	J
D ₁	Canada	Urine	2000	C15–13	1	<i>fumC</i> 132	Ac, Cm, Cp, Gm, Km, Na, Sm, Su, Th, Tp	P (85)	85 + 120	FII (85)	C2
D_1	Kuwait	Wound	2004	C15–14	1	fumC 4	Ac, Cp, Na, Sm, Su, Tc, Tp	С	120 + 100	FII + FIA + FIB (120)	ND
D ₁	Switzerland	Urine	2004	C15–15	2	ST405	Ac, Cp, Gm, Km, Na, Sm, Su, Tc, Tb, Tp	С	85 + 120	FII + FIA + FIB (85)	ND

Appendix Table. Epidemiologic data of CTX-M-15-producing Escherichia coli isolates from 7 countries*

D ₁	Kuwait	Respiratory tract	2004	C15–16	1	ST405	Ac, Cp, Gm, Km, Na, Sm, Su, Tc, Tb, Tp	P (150)	150	FII + FIA + FIB (150)	0
D ₁	Kuwait	Urine	2004	C15–17	1	ST405	Ac, Ak, Cp, Gm, Km, Na, Sm, Su, Tc, Tb, Tp	P (160), C	160	FII + FIA + FIB (160)	ND
D ₁	Switzerland	Urine	2004	C15–18	1	fumC 26	Ac, Cp, Gm, Km, Na, Su, Tc, Tb, Tp	С	120	FII + FIA + FIB (120)	L
D ₁	Paris, France	Urine	2001	C15–19	1	fumC 88	Cm, Cp, Gm, Na, Su, Tc, Tb, Tp	P (85)	85	FII (85)	С
-	India	-	2000	C15–20	1	-	Ac, Cm, Sm	P (85)	85	FII (85)	G
-	India	-	2000	C15–21	1	_	Ac, Gm, Km, Sm, Tc, Tb	P (85)	85	FII (85)	н
A ₁	Kuwait	Blood	2004	C15–22	1	-	Ac, Gm, Km, Sm, Tc, Tb	_	-	FIL	FE
A ₁	Paris, France	Urine	2001	C15–23	1	-	Ac, Ak, Cm, Cp, Gm, Km, Na, Ni, Sm, Su, Tc, Tb, Tp	С	100	FII + FIA + FIB (100)	F
A ₁	Canada	Urine	2001	C15–24	1	-	Ac, Cp, Gm. Km, Na, Sm, Su, Tc, Tb	P (110)	110	FII + FIA + FIB (110)	К
A ₁	Kuwait	Respiratory tract $(n = 1)$, urine $(n = 1)$	2004	C15–25	2	-	Ac, (Ak), Cp, Gm, Km, Na, (Ni), (Sm), Su, Tc, Tb, Tp	P (120)	120	FII + FIA (120)	N
A ₁	Reims, France	Urine	2005	C15–26	2	_	Ac, Cm, Cp, Gm, Km, Na, Su, Tb, Tp	P (120)	120 + 100	FII + FIA + FIB (120)	ND
A ₁	Kuwait	Urine	2004	C15–27	1	_	Ac, Cp, Km, Na, Sm, Su, Tc. Tb. Tp	P (85)	85 + 100	FII + FIB (85)	D
B ₁	Paris, France	Urine	2003	C15–28	1	_	Ac, Km, Tc, Tb	P (85)	85	FII (85)	М
B ₁	Paris, France	Urine	2003	C15–29	1	-	Ac, Km, Sm, Su, Tc, Tb, Tp	P (80)	80	FII (85)	Ρ
B ₁	Paris, France	Urine	2002	C15–30	1	-	Ac, Cm, Cp, Gm, Km, Na, Ni, Sm, Su, Tc, Tb, Tp	P (100), C	100 + 40	FII + FIA (100)	Ι

*EC PhG, *E. coli* phylogenetic group; PFGE, pulsed-field gel electrophoresis; MLST, multilocus sequence typing; RFLP, restriction fragment length polymorphism; ST, sequence type. †Transferability of antimicrobial drug resistance to a given drug is indicated in **boldface**. Drugs in parentheses are not associated with resistance in all isolates. Ac, amoxicillin-clavulanic acid; Gm, gentamicn; Km, kanamycin; Na, nalidixic acid; Ni, nitrofurantoin; Sm, streptomycin; Su, sulfonamide; Tb, tobramycin; Tp, trimethoprim; Tc, tetracycline; Cp, ciprofloxacin; Ak, amikacin; Cm, chloramphenicol. ‡Chromosomal (C) or plasmid (P) location of the *bla*_{CTXM-15} gene was determined by hybridization of probes with I-*Ceu*I-digested genomic DNA. Size of the plasmid in kb is indicated in parentheses. §Plasmid size and content were determined by hybridization of S1 nuclease–digested genomic DNA on transconjugants (or wild type if transfer failed). Successful plasmid transfer by conjugation or transformation is indicated in **boldface**.

¶Replicon content of plasmids with *bla*_{CTX-M-15} genes was determined by PCR, hybridization, and sequencing of replicons. Replicons hybridizing in the same band as that of the *bla*_{CTX-M-15} gene are indicated in **boldface**. Numbers in parentheses represent plasmid sizes in kb.

#ND, not done; FE, failed extraction.